Info

Azevan Pharmaceuticals, Inc. (Azevan or the Company) is developing novel therapeutics for the treatment of disorders of stress, mood, and behavior. The Company leverages its expertise in behavioral neurobiology with its proprietary chemistry platform targeting G-protein coupled receptors (GPCRs) to create drug candidates. Azevan's first series of clinical candidates selectively block the effects of arginine vasopressin (AVP), which is involved in the pathophysiology of various conditions including stress-related affective illness, impulsivity/inappropriate aggression, and menstrual-related disorders. The value proposition for Azevan lies in its strong preclinical pipeline, the diverse indications and significant potential markets for selective vasopressin antagonists, and the flexibility of its proprietary chemistry that allows targeting of additional high value G-protein coupled receptors.